Damiano Rondelli
University of Illinois Chicago · Myeloproliferative Disorders-Research Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Damiano Rondelli as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03121001 · Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell DiseaseUniversity of Illinois Chicago · recruiting · Sickle Cell Disease · principal investigator
- Ph2NCT03121014 · Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesUniversity of Illinois Chicago · active not recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndromes · principal investigator
- Ph1NCT02043847 · TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)University of Illinois Chicago · completed · Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment · principal investigator
- Ph2NCT02013375 · SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCDDamiano Rondelli, MD · terminated · Sickle Cell Disease · principal investigator
- Ph1/Ph2NCT01499888 · Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)University of Illinois Chicago · active not recruiting · Sickle Cell Disease · principal investigator
- N/ANCT01499147 · Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesUniversity of Illinois Chicago · completed · Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia · principal investigator
- N/ANCT00988013 · Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic MalignanciesUniversity of Illinois Chicago · completed · Acute Myeloid Leukemia, Lymphoblastic Leukemia, Acute Leukemia · study chair
- Ph2NCT00572897 · Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for MyelofibrosisJohn Mascarenhas · completed · Myelofibrosis · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 3: Development of Strategies to Deplete Myelofibrosis Stem CellsP01CA108671 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ronald Hoffman · fiscal years 2006 to 2026Named on NCT00572897
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:54 UTC. The ranking covers the 200 most relevant of 33 PubMed records, and a shared surname and initials can bring in a namesake. All 33 on PubMed
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.N Engl J Med · 20211,491 citationsRCR 82.9
- Exagamglogene Autotemcel for Severe Sickle Cell Disease.N Engl J Med · 2024393 citationsRCR 52.3
- 152 citationsRCR 6.2
- 130 citationsRCR 11.7
- 113 citationsRCR 3.4
- Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.Biol Blood Marrow Transplant · 2016112 citationsRCR 4.7
- Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma.Ann Oncol · 199398 citationsRCR 3.3
- Strength training following hematopoietic stem cell transplantation.Cancer Nurs · 201171 citationsRCR 2.3
- Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.Br J Haematol · 202166 citationsRCR 4.8
- Strength Training to Enhance Early Recovery after Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant · 201759 citationsRCR 2.9